Digest Network How does it work
Network
/
Society
NM
Society

NMS GROUP S.P.A.

What we write about

ArtCultureHealthOncologySanità

33 Press releases

View all press releases
Press Release cover image
31/03/2025
Health
Oncology
Sanità
Nerviano Medical Sciences Srl Announces Rozlytrek® (Entrectinib) Royalty Agreement - NMS Group
Source
NMS GROUP S.P.A.
1.00
0
Press Release cover image
21/02/2025
Art
Culture
Archaeology
Law
CPhI Japan 2025 - NMS Group
Source
NMS GROUP S.P.A.
1.00
0
Press Release cover image
19/02/2025
Art
Culture
Law
Aerospace
DCAT WEEK 2025 - NMS Group
Source
NMS GROUP S.P.A.
1.00
0
Press Release cover image
10/02/2025
Health
Oncology
Sanità
PARP1 publications - NMS Group
Source
NMS GROUP S.P.A.
1.00
0
Press Release cover image
31/01/2025
Health
Oncology
Sanità
Nerviano Medical Sciences’ presentation from the 8th Annual DDR Inhibitors Summit is now available - NMS Group
Source
NMS GROUP S.P.A.
1.00
0
Press Release cover image
22/01/2025
Health
Oncology
Sanità
Nerviano Medical Sciences is presenting at the 8th Annual DDR Inhibitors Summit - NMS Group
Source
NMS GROUP S.P.A.
1.00
0
Press Release cover image
13/01/2025
Health
Oncology
Sanità
Nerviano Medical Sciences announces FDA clearance of two INDs for its PARP1-selective, non-trapping inhibitor NMS-293 to start clinical studies in small cell lung cancer and BRCA wild-type ovarian carcinoma - NMS Group
Source
NMS GROUP S.P.A.
1.00
0
Press Release cover image
07/01/2025
Health
Oncology
Sanità
Nerviano Medical Sciences S.r.l. Announces the Launch of a New Clinical Trial to Evaluate NMS-153 in Combination with Atezolizumab and Clinical Trial Supply Agreement with Roche - NMS Group
Source
NMS GROUP S.P.A.
1.00
0
Press Release cover image
25/11/2024
Health
Sanità
Nerviano Medical Sciences (NMS) to Reacquire World-Wide Rights of NMS-293, a Potent, Highly Selective, Non-Trapping, Brain-Penetrant PARP1 Inhibitor with Promising Clinical Results - NMS Group
Source
NMS GROUP S.P.A.
1.00
0
Press Release cover image
25/11/2024
Health
Sanità
Nerviano Medical Sciences (NMS) to Reacquire World-Wide Rights of NMS-293, a Potent, Highly Selective, Non-Trapping, Brain-Penetrant PARP1 Inhibitor with Promising Clinical Results - NMS Group
Source
NMS GROUP S.P.A.
1.00
0

Contact details

NMS GROUP S.P.A.

Viale L. Pasteur, 10 Nerviano 20014 MI 20014 Nerviano
0331581111

Social Media

Followers
0
Compatibility
0